abstract |
(57) [Summary]nThe present disclosure relates to a new class of hydroxamic acid and carboxylic acid based matrix metalloproteinase inhibitor derivatives. The disclosure further relates to pharmaceutical compositions containing such compounds, and the use of such compounds and compositions in the treatment of matrix metalloproteinase-induced disorders. |